Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models
TDP-43WT

Updated 9 March 2010

General Information

TARDBP (NM_007375) was amplified from a human cDNA library (hTDP-43) and cloned into an mTUB expression vector containing a murine Thy-1 promoter. The expression vector was microinjected into pronuclear oocytes of Bl6/SJL mice. Founders were bred with C57Bl6/J mice.

Mutation: Overexpressing hTDP-43.

Promoter: Murine Thy-1 promoter.

Mouse strain: C57Bl6/J. Background strain: Bl6/SJL. Current Generation Number: ˜F4. Colony maintenance: Homozygous hTDP-43-overexpressing mice were generated for two selected lines by crossbreeding hemizygous hTDP-43-overexpressing mice.

Phenotype

Neuropathological analysis:

Overexpression of WT TDP-43 leads to degeneration of specific neurons in the central nervous system, including spinal and cortical motor neurons and non-motor cortical neurons characteristically affected in FTLD-TDP, and causes spastic quadriplegia in a dose-dependent manner (ALS).

Behavioral Phenotype:

Abnormal limb reflex seen in highest expressing homozygous mice at ~ 14 days characterized by retraction of hindlegs toward the trunk upon lifting them by their tail. At 18 days mice show poor motor performance on accelerating rotarod. At ~22 days, fasciculations and spasms of facial muscles were observed, followed by an extremely rapid disease progression, with mice becoming completely paralyzed and dying within 3–4 days.

Availability

Contact: Samir Kumar-Singh
Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB
University of Antwerp (CDE), B-2610 Antwerpen, Belgium
Telephone: +32 3 265 1002
Fax: +32 3 265 1012
Samir Kumar-Singh
Stock/Catalog Number: TAR4 (high Tg expressor) and TAR6 (low Tg expressor).

References

Primary:

Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3858-63. Abstract

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad